Clinical Trial Protocol
Iranian Registry of Clinical Trials

08 Nov 2026

Effects of Intravitreal Bevacizumab (Avastin) therapy on visual acuity in patients with Proliferative Diabetic Retinopathy

Protocol summary

Summary

Purpose: to evaluate the efficacy and safety of itravitreal bevacizumab in proliferative diabetic retinopathy (PDR)patients. Design: Quasi clinical study Methods: 39 eyes of 26 PDR patients were evaluated. All patients completed 12 weeks of follow-up. Patients were treated with one intravitreal injection of 1.25 mg of bevacizumab. Evaluation consisted of a complete ophthalmologic examination, including Snellen Visual acuity (VA) measurement, ophtalmoscopy and fluorescein angiography(FA). Main outcome measures: changes in VA and FA.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138903314232N1**
Registration date: **2010-11-26, 1389/09/05**
Registration timing: **retrospective**

Last update:
Update count: **0**

Registration date

2010-11-26, 1389/09/05

Registrant information

Name
Ebrahim Mikaniki
Name of organization / entity
Babol University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 11 1219 9015
Email address
e.mikaniki@mubabol.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Babol University of Medical Sciences

Expected recruitment start date

2007-10-31, 1386/08/09

Expected recruitment end date

2009-10-31, 1388/08/09

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effects of Intravitreal Bevacizumab (Avastin) therapy on visual acuity in patients with Proliferative Diabetic Retinopathy

Public title

Intravitreal Bevacizumab (Avastin) therapy for Proliferative Diabetic Retinopathy

Purpose

Treatment

Inclusion/Exclusion criteria

Patients were not offered treatment if they had uncontrolled hypertension or recent myocardial infarction or cerebral vascular accident.

Age

From **35 years** old to **70 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **39**

Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Single

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Babol university of medical sciences

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Postal code

Approval date

2010-10-12, 1389/07/20

Ethics committee reference number

1816

Health conditions studied

1

Description of health condition studied

diabetic retinopathy

ICD-10 code

H36.0

ICD-10 code description

Retinal disorders in diseases classified elsewhere

Primary outcomes

1

Description

Visual Acuity

Timepoint

0, 4, 12 weeks

Method of measurement

complete ophtalmic examination

Secondary outcomes

1

Description

Speed of improvement and durability of visual acuity

Timepoint

4 and 12 weeks after intervention

Method of measurement

ophtalmic examination

Intervention groups

1

Description

One intravitreal injection of 1.25 mg of bevacizumab (Avastin)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Beheshti Hospital

Full name of responsible person

Dr Mikaniki

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research; Babol university of medical sciences

Full name of responsible person

Vice chancellor for research

Street address

Ganj Afrooz st., Babol university of medical sciences

City

Babol

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancellor for research; Babol university of medical sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact
Name of organization / entity
Babol university of medical sciences
Full name of responsible person
Ebrahim Mikaniki
Position
Assistant Professor
Other areas of specialty/work
Street address
Ganj Afrooz st., Babol university of medical sciences
City
Babol
Postal code
Phone
+98 11 1219 9015
Fax
Email
dr_emikaniki@yahoo.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Babol university of medical sciences
Full name of responsible person
Ebrahim Mikaniki
Position
Assistant Professor
Other areas of specialty/work
Street address
Ganj Afrooz st., Babol university of medical sciences
City
Babol
Postal code
Phone
+98 11 1219 9015
Fax
Email
dr_emikaniki@yahoo.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Babol university of medical sciences
Full name of responsible person
Ebrahim Mikaniki
Position
Assistant Professor
Other areas of specialty/work
Street address
Ganj Afrooz st., Babol university of medical sciences
City
Babol
Postal code
Phone
+98 11 1219 9015
Fax
Email
dr_emikaniki@yahoo.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty